07/02/2019

06/11/2019

Asclemed USA Inc. dba Enovachem

Division of Pharmaceutical Quality Operations IV

CGMP/Active Pharmaceutical Ingredient (API)/Adulterated

07/02/2019

06/04/2019

B & B Pharmaceuticals, Inc.

Division of Pharmaceutical Quality Operations IV

Unapproved New Drug/Misbranded

07/02/2019

05/16/2019

Izeen Pharma Inc

Division of Pharmaceutical Quality Operations I

CGMP/Finished Pharmaceuticals/Adulterated

07/09/2019

06/20/2019

HealthTech International Inc.

Division of Human and Animal Food Operations West IV

Dietary Supplement/Adulterated

7/09/2019

06/12/2019

SnugZ USA, Inc.

Division of Pharmaceutical Quality Operations III

CGMP/Finished Pharmaceuticals/Adulterated

07/09/2019

06/17/2019

Ideal Specialty Apothecary, Inc. dba Ideal Pharmacy

Division of Pharmaceutical Quality Operations I

Drug Product/Adulterated

Is it fair for some in the compounding pharmacy industry to claim that there were only a few violators of laws and regulations when there have been numerous prosecutions and numerous 482s showing otherwise (and that is the evidence of only those who have been caught at this point)? If stricter laws and regulations are not the answer and state boards of pharmacy enforcing their laws on the books hasn't work then what is the answer?

Statement from Acting FDA Commissioner Ned Sharpless, M.D., and Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research, on steps to make health care professional and patient labeling information for prescription medications consistent and clear

The FDA is committed to making sure that health care professionals and patients have up-to-date, accurate and actionable information about prescription medications so that informed treatment decisions can be made. We recognize that the choice of which medication to use, if any, for a particular patient is often a complex decision. These decisions involve a number of factors, such as assessing the progression of the disease or condition; looking at the other medications being taken; evaluating the ability of the patient to follow treatment regimens and instructions to ...

Read More

Fighting Theranos Charges, Holmes Blames Advocacy Journalism By Joel Rosenblatt June 28, 2019, 2:27 PM CDT

https://www.bloomberg.com/news/articles/2019-06-28/fighting-theranos-charges-holmes-blames-advocacy-journalism

FCA Decision Tracker: More Interpretations Of Escobar

Law360-3 hours ago

Allegations that pharmacies overcharged Medicaid for generic drugs that ... unnecessary prescriptions for expensive compounded drugs did not include any ...